This longitudinal, retrospective cohort study of patients with COPD describes baseline characteristics, adherence, and persistence following initiation inhaled corticosteroids (ICS)/long-acting β2-agonists (LABA)/long-acting muscarinic antagonists (LAMA) from multiple inhaler triple therapy (MITT).Patients aged ≥40 years receiving MITT between January 2012 September 2015 were identified the IQVIA™ Real-world Data Adjudicated Claims-USA database. was defined as subjects ≥1 overlapping days'...

Triple therapy comprising an inhaled corticosteroid, long-acting muscarinic antagonist, and β2 agonist (ICS/LAMA/LABA) is recommended for chronic obstructive pulmonary disease (COPD) patients at risk of exacerbation. Multiple-inhaler triple (MITT) associated with poor adherence persistence; however, these outcomes have not been evaluated single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI).This retrospective analysis the IQVIA PharMetrics Plus claims database identified...

Results from clinical trials in patients with severe eosinophilic asthma have demonstrated that mepolizumab is well tolerated and associated improved control as evidenced by reductions both exacerbations maintenance oral corticosteroid use, improvements lung function, control, quality of life. However, real-world data are lacking on the impact treatment.To assess effect treatment rate exacerbation-related costs a setting.This retrospective cohort study (GSK ID: 209017; HO-18-19168) analyzed...

BackgroundPatients with severe asthma frequently have associated comorbidities, which can compound existing symptoms, complicating management.ObjectiveTo describe the real-world effectiveness of mepolizumab in patients stratified by common overlapping comorbidities.MethodsThis was a retrospective analysis from MarketScan Commercial and Medicare Supplemental Database initiating treatment (index date). Eligible had more than or equal to 1 claim (excluding claims for diagnostic tests) diagnosis...

Triple therapy (TT; inhaled corticosteroid, long-acting muscarinic antagonist, and β2-agonist) is recommended for patients with chronic obstructive pulmonary disease (COPD) at risk of exacerbation, although the optimum timing TT initiation remains unclear. This study evaluated impact prompt versus delayed single-inhaler (fluticasone furoate, umeclidinium, vilanterol [FF/UMEC/VI]) following a COPD exacerbation.This retrospective cohort used data from IQVIA PharMetrics® Plus database. Patients...

Purpose: Patients with chronic obstructive pulmonary disease (COPD) have been shown to benefit from triple therapy commonly delivered by multiple-inhaler (MITT); however, the complexity of MITT regimens may decrease patient adherence. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), a once-daily single-inhaler (SITT), became available in United States (US) 2017, but real-world data comparing outcomes for SITT versus are currently limited. This study compared among patients COPD...

There is a high prevalence of chronic obstructive pulmonary disease (COPD) in the United States (US). Although guidelines are available for treatment COPD, evidence suggests that management COPD clinical practice not always aligned with this guidance. This study aimed to further understand current use maintenance medication US.This was an analysis data from Adelphi Respiratory Disease Specific Programme (DSP™) 2019. Point-in-time were collected participating US physicians and their patients....

Real-world asthma control data among patients initiating fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) are limited. This study assessed rescue medication use and asthma-related exacerbations in with before after single-inhaler FF/UMEC/VI using administrative claims data.This retrospective, pre-post cohort analyzed from the IQVIA PharMetrics Plus database (September 18, 2016‒March 31, 2020). Patients aged ≥18 years that had ≥1 dispensing of 100/62.5/25 mcg (first = index date), ≥12...

This study assessed patient-level characteristics and patterns of medication use in patients with chronic obstructive pulmonary disease (COPD) before initiation multiple inhaler triple therapy (MITT; long-acting muscarinic antagonist/long-acting β2-agonist/inhaled corticosteroid [ICS/LAMA/LABA] combination).This retrospective was conducted using the Optum Research Database. Patients enrolled commercial or Medicare Advantage Prescription Drug plans, a COPD diagnosis >1 prescription for...

Background: In controlled clinical studies, mepolizumab has been shown to reduce exacerbation rates and the use of oral corticosteroids as well improve asthma control health-related quality life compared with placebo in patients severe eosinophilic asthma. However, real-world data on impact outcomes are limited. Objective: To evaluate effect exacerbations exacerbation‐related costs U.S. practice. Methods: This retrospective cohort study used administrative claims from ages ≥12 years at...

It is unknown whether there a benefit to initiating triple therapy (TT; inhaled corticosteroids combined with long-acting β2-agonists and muscarinic antagonists) promptly (within 30 days) following chronic obstructive pulmonary disease (COPD)-related hospitalization or emergency-department (ED) visit compared delaying treatment (31-180 days).This retrospective, observational study (GSK: HO-15-15256) used healthcare claims from commercial Medicare database (January 1, 2008-December 31,...

Patients with severe asthma often require oral corticosteroid (OCS) treatment. Clinical trials have demonstrated that mepolizumab can reduce OCS dependence, but real-world data are limited.To evaluate the impact of on use, exacerbations, and exacerbation-related costs in a setting.This retrospective cohort study (GSK ID: 209642; HO-19-19597) analyzed from MarketScan® Commercial database (identification period: November 2015-September 2017). were ≥12 years old at initiation (index date), had...

To examine the impact of initiating fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in a single device on chronic obstructive pulmonary disease (COPD) exacerbations, COPD exacerbation-related costs, and all-cause COPD-related healthcare resource utilization (HCRU) costs patients with COPD.Retrospective database analysis aged ≥40 years who initiated FF/UMEC/VI between September 1, 2017, December 31, 2018 (index date: first pharmacy claim for FF/UMEC/VI), following evidence...

There is limited literature regarding real-world treatment patterns of patients with COPD, particularly since the introduction once-daily single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol in 2017. Here, we evaluated COPD before and after a exacerbation.Retrospective, descriptive study using medical pharmacy claims data enrollment information from Optum® Clinformatics® Data Mart database. Patients aged ≥40 years ≥1 exacerbation on or September 18, 2017 were included....

To assess patient- and physician-reported reasons for discontinuing biologic therapy among patients with severe asthma from a real-world US cohort.This retrospective analysis surveyed physicians their who were receiving/had previously received between August December 2019. Physicians managing ≥3 per month completed surveys on disease management, demographics, exacerbation history, adherence eligible patients. Patients could voluntarily complete questionnaire, providing perceptions of...

Patients with chronic obstructive pulmonary disease (COPD) are potentially at increased risk of herpes zoster (HZ). Little is known about the impact an HZ episode on health care resource utilization (HRU) and costs among patients COPD.This retrospective cohort study individuals aged ≥50 years in United States (US) used administrative claims data from Optum's de-identified Clinformatics Data Mart Database for commercially insured Medicare Advantage members (2013-2018). Two cohorts COPD,...

BackgroundAddition of a long-acting muscarinic antagonist is recommended for patients with asthma uncontrolled on inhaled corticosteroid/long-acting β2-agonist therapy. This the first large-scale, real-world study examining multiple-inhaler triple-therapy (MITT) use in asthma.ObjectiveTo describe prevalence, outcomes, and treatment patterns associated MITT.MethodsThis retrospective cohort used medical pharmacy claims from Optum Research Database. Patients were diagnosed between January 01,...

Background/Objective Although the high disease burden associated with eosinophilic granulomatosis polyangiitis (EGPA) has been established, in patients initiating mepolizumab real-world practice is poorly understood. This study aimed to assess characteristics and of EGPA mepolizumab. Methods was a database (GSK ID: 214156) US (≥12 years old) ≥1 claim (index date) identified from Merative MarketScan Commercial Medicare Supplemental Databases (November 1, 2015, March 31, 2020). Outcomes...

Suboptimal treatment of exacerbations is a major concern in management chronic obstructive pulmonary disease (COPD). The Pharmacotherapy Management COPD Exacerbation (PCE) Healthcare Effectiveness Data and Information Set (HEDIS) measure quality included by the National Committee for Quality Assurance that focuses on appropriate use steroids bronchodilators during an acute exacerbation. There limited evidence evaluating predictors this measure, as well its association with hospital...

Objective To evaluate the real-world impact of mepolizumab on incidence asthma exacerbations, oral corticosteroid (OCS) use and exacerbation-related costs in patients with high-burden severe asthma.Methods This was a retrospective study MarketScan Commercial Medicare Databases (≥80th percentile total healthcare expenditure and/or significant comorbidity burden). Patients were ≥12 years age upon initiation (index date November 1, 2015–December 31, 2018) had ≥2 administrations during 6 months...

Chronic obstructive pulmonary disease (COPD) has been reported as a potential risk factor for developing herpes zoster (HZ). We aimed at comparing incidence rates of HZ between people with versus without COPD in the US. This retrospective cohort study used data from Optum's de-identified Clinformatics Data Mart database 1/1/2013 through 12/31/2018. identified two cohorts ≥40 years prior HZ, vaccination, postherpetic neuralgia (PHN) or ophthalmicus: those (COPD+) and (COPD-) diagnosis....

Purpose: Pharmacist-led medication therapy disease management (MTDM) has shown improvement in clinical outcomes patients with certain chronic diseases. However, only limited data demonstrating the impact on health care utilization and cost of are available. This study seeks to evaluate a pharmacist-led MTDM program surrogate outcomes, utilization, among diabetes mellitus. Methods: A retrospective cohort was conducted by utilizing electronic records insurance claims data. Patients were...